<h4>Background</h4>Epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) responds well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), yet optimal therapy after resistance remains uncertain. This evidence concerns the gene EGFR and non-small cell lung carcinoma.